The cornea is one of the most highly innervated tissues in the mammalian host. We hypothesized changes to cornea innervation through chemical sympathectomy would significantly alter the host response to the neurotropic viral pathogen, herpes simplex virus type 1 (HSV-1) following ocular infection. Mice treated with 6-hydroxydopamine hydrobromide displayed reduced tyrosine hydroxylase-positive fibers residing in the cornea. Sympathectomized mice were also found to show a transient rise in virus recovered in infected tissues and succumbed to infection in greater numbers. Whereas there were no differences in infiltrating leukocyte populations including HSV-1-specific cytotoxic T lymphocytes in the infected tissue, an increase in substance P and a decrease in IFN-γ levels in the trigeminal ganglion but not brain stem of sympathectomized mice were noted. Sympathectomized mice treated with the neurokinin-1 receptor antagonist L703,606 had delayed mortality implicating the involvement of substance P in HSV-1-mediated death.
Introduction
A complex network of specialized cells and soluble factors comprise the mammalian immune system that is broadly divided into innate and adaptive components. Both endogenous and exogenous pathways regulate the integrity and quality of the immune response to various stimuli. For example, it is now recognized organized immune tissue (e.g., spleen, lymph nodes, and thymus) is "hard-wired" with cholinergic, peptidergic, and adrenergic nerve fibers (Felten and Felten, 1991) . The importance of innervated immune organs is underscored by findings that suggest disruption of noradrenergic fibers using the neurotoxin, 6-hydroxydopamine (6OHDA) results in changes in antibody production (Livnat et al., 1985; Kohm and Sanders, 1999) , delayed-type hypersensitivity responses (Madden et al., 1989) , natural killer (NK) cell activity (Reder et al., 1989) , and T cell proliferation (Moynihan et al., 2004) which collectively, can modify host susceptibility to infection (Leo et al., 1998; Miura et al., 2001 ) and severity of autoimmune disease including experimental autoimmune encephalitis (ChelmickaSchorr et al., 1988) and experimental rheumatoid arthritis (Felten et al., 1992; Härle et al., 2005) . 6OHDA treatment results in the activation of the hypothalamic pituitary adrenal Journal of Neuroimmunology 197 (2008) 37 -46 www.elsevier.com/locate/jneuroim
